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Background: Oral ulcers caused by methotrexate (MTX) at low doses are a known side effect of this drug. Al-
though increasingly more patients are medicated with MTX, these painful ulcers, without traumatic origin and re-
sistant to any type of treatment, are not usually identified by health professionals as a side effect of the medication.
Material and Methods:In the absence of a consensus protocol for the effective treatment of oral lesions produced 
by MTX, the objective of this article was to review and analyse the information from articles related to oral ulcers 
produced by low-dose MTX and to record the clinical management performed and the MTX dose given to the 
patient. Data sources - Medline, Web of Science, and Cochrane Library. Participants - Patients treated with low-
dose MTX (less than 25 mg/week). Interventions - Management of oral lesions caused by MTX. Study eligibility 
criterion, study appraisal and synthesis method: An initial search was carried out in the aforementioned databases 
with the terms ‘methotrexate AND oral OR ulcer’. The search was carried out using both medical subject heading 
(MeSH) terms and a free search between January 2003 and January 2018. Of the results obtained, two indepen-
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Introduction
Methotrexate (MTX) is an immunomodulator that 
functions as an antagonist of folic acid and is widely 
used at high doses as a chemotherapeutic agent for the 
treatment of lymphomas, leukaemia and some solid 
tumours. MTX binds irreversibly to dihydrofolate re-
ductase by exerting antiproliferative activity (1). At low 
doses (no more than 25 mg/week), its main effect is anti-
inflammatory and is used for the treatment of several 
autoimmune diseases, such as rheumatoid arthritis, sys-
temic lupus erythematosus, pemphigoid, polymyositis 
or psoriasis (2). Although its use is recommended in 
different guidelines for the treatment of diseases previ-
ously mentioned for more than 50 years and is consid-
ered safe at low doses, data on the efficacy and safety of 
MTX are scarce (3,4).
In blood, MTX is conjugated with albumin and excreted 
via the kidneys. Interaction with drugs that decrease the 
renal elimination of MTX, that inhibit the synthesis of 
folic acid or that decrease the binding of MTX to pro-
teins can trigger adverse effects (5). Concomitant fac-
tors, such as old age, other drugs or kidney failure, can 
increase the toxicity of the drug (6).
This drug usually affects tissues of rapid tissue renewal, 
such as the bone marrow or the gastrointestinal tract. 
Oral ulcers may appear in 11%-17% of patients treated 
with MTX at low doses (2,3,7). The most common ef-
fects of MTX at low and high doses are acute myeloid 
suppression, gastrointestinal disorders, hepatotoxicity 
and acute kidney failure (4). Other common side effects 
in patients treated with low-dose MTX include nau-
sea, diarrhoea and abdominal pain (2) and the recorded 
treatment abandonment rate is between 3%-6% (3,8).
Adverse reactions from long-term low-dose MTX treat-
ment may be present in 30% to 80% of patients, and 
dent researchers analysed abstracts that met the search criteria, that is, those that mentioned oral ulcers produced 
by MTX at low doses. Next, both researchers read the complete article and determined whether it met the following 
inclusion criteria: written in English, specified the dose of MTX prescribed for the patient and specified the protocol 
of action for the ulcers. A third investigator acted as a mediator in cases of dispute. Agreement was calculated using 
Cohen’s kappa coefficient, with a k value of 0.82. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guide for systematic reviews was used.
Results: The initial search resulted in a total of 66 articles, of which 30 were selected to assess their inclusion in this study. 
Finally, 16 met the inclusion criteria. Using the Pierson and Newcastle-Ottawa scales and Bradford Hill criteria modified 
for studies of case series and “in relation to a case”, 2 were rated as high quality, 2 were rated as low quality and 12 were 
rated as medium quality. The limitations of this study are based on the fact that all of the articles available to carry out the 
systematic review were “in relation to a case or series of cases”, with the heterogeneity of data that this implies.
Conclusions:Evidence on the management of oral ulcers in the oral cavity produced by MTX at low doses is scarce 
due to the heterogeneity of data and the measures adopted in the selected studies. Therefore, it seems that this man-
agement is relegated to the perception of the clinician rather than to a specific protocol of action. Studies with a longer 
follow-up duration and larger sample size are needed to guide different health professionals on the management of 
these lesions.
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acute toxicity in patients taking MTX at low doses may, 
in some cases, be life-threatening (9).
The most recent publications classify the adverse ef-
fects of MTX into four categories: category A dose-
dependent, category B or idiosyncratic, category C or 
effects due to cumulative dose, and category D or de-
layed effects after cessation of treatment. Category A 
includes mucocutaneous and gastrointestinal toxicity 
and occasionally pancytopenia, which may also be due 
to idiosyncratic effects (category B). The cumulative 
dose includes chronic liver and lung toxicity, although 
the association between liver toxicity and cumulative 
dose of MTX is controversial. Delayed effects (category 
D) include teratogenicity (6).
For the treatment of acute toxicity due to MTX, several 
measures are proposed. Yélamo et al. explained that fo-
lic acid supplementation improves gastrointestinal tol-
erance and prevents haematological toxicity (6). These 
authors also recommend that in the presence of pancy-
topenia, mucositis or cutaneous ulcers, MTX should be 
eliminated since its effects can be life-threatening, with 
hydration causing an increase in the renal elimination 
of the drug and the addition of folic acid as an antidote 
being important. It also specifies that once the toxicity 
has passed, MTX can be reintroduced.
Other authors such as Kalantzis et al. summarized a 
series of measures for the treatment of acute MTX tox-
icity, including cessation of treatment, reduction of its 
dose, folic acid complement or a combination of mea-
sures. However, the authors did not explain under what 
circumstances each measure must be applied or what 
benefits they provide with respect to other measures (8).
Nevertheless, MTX at low doses is the first line of ac-
tion for the treatment of different autoimmune patholo-
gies in European guidelines (10). The prevalence of pso-
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riasis in the Spanish population is 2.4% (11) and some 
authors believe that the adverse effects of MTX are 
being underestimated by dermatologists, pathologists, 
dentists or maxillofacial specialists (7).
In the absence of a consensual action protocol for the 
effective treatment of oral lesions caused by MTX at 
low doses, the objective of this article was to review and 
analyse the information from articles related to patients 
who have suffered oral ulcers produced by low-dose 
MTX, recording the method of action carried out and 
the MTX dose given to the patient. The PECOS mne-
monic was used to formulate the following question: In 
patients with oral ulcers who take MTX at low doses, 
what is the most effective management for their com-
plete cure? To address this question, we carried out a 




The design of this study was carried out by CHP and 
is registered in PROSPERO (CRD42018103692). The 
review was carried out following PRISMA guidelines 
and the PECOS method (12): patients with oral ulcers 
taking low-dose MTX (P=patient); withdrawing MTX 
(E=exposure); non-ceasing MTX (C=comparison); time 
healing ulcers (O=outcome); case report (S= type of 
study). 
-Eligibility criteria, information sources and search: 
Exclusion criteria were as follows: articles that did not 
address ulcers produced by MTX; abstract not avail-
able; written in a language other than English or Span-
ish; prescribed dose for the MTX patient was unspeci-
fied; absence of a protocol to follow for healing oral 
ulcers; and sex or age of the patient was unspecified.
We carried out a literature search in PubMed, Embase 
and Web of Science to identify relevant studies on ulcers 
produced by MTX written in English between January 
2003 and January 2018 using the terms ‘methotrexate 
AND oral OR ulcer’. Medical subject heading (MeSH) 
terms and free search were also used. All articles on “in 
relation to a case”, cohort studies and case-control stud-
ies were included.
-Study selection:
From the results obtained from the search, two inde-
pendent researchers (MPS and CHP) analysed abstracts 
that met the search criteria, that is, abstracts that men-
tioned oral ulcers produced by MTX at low doses. Then, 
both researchers read the complete article and deter-
mined whether it met the following inclusion criteria: 
written in English, specified the dose of MTX taken by 
the patient and specified the protocol of action for the 
ulcers. A third investigator (AGG) acted as a mediator 
in cases of dispute. Agreement was calculated using Co-
hen’s kappa coefficient, with a k value of 0.82.
-Data collection process:
Data retrieved from all articles were collected by both 
researchers (in duplicate) independently and corrobo-
rated by the third party, who acted as a mediator in 
cases of discrepancy or lacked agreement.
-Data items:
The following information was extracted from each 
study: first author, year of publication, sex and age of 
the patient, type of lesion (single or multiple), location, 
possible cause, time of evolution, management of the 
lesion, restoration of MTX without relapse of the lesion, 
disease for which MTX is taken, HSV (herpes simplex 
virus), EBV (Epstein-Barr virus), CMV (cytomegalovi-
rus), folic acid intake prior to the onset of the lesion, 
histological analysis, MTX dose, oral or subcutaneous, 
length of time taking MTX (months), time to healing, 
kidney involvement, liver involvement, myelosuppres-
sion, smoker and cigarettes/day, other medications, and 
follow-up time.
If the time taking MTX was less than one month, it was 
considered 0, indicating that the appearance of ulcers 
was due to the recent introduction of MTX as a treat-
ment.
-Risk of bias in individual studies:
The methodological quality of the included studies and 
the possibility of bias were assessed using the modified 
Newcastle-Ottawa, Pierson and Bradford Hill scales for 
case series and “in relation to a case” studies (13). The 
authors of this scale recommend assessing the quality 
of the studies according to four categories, selection, as-
certainment, causality and reporting, with eight specific 
questions to answer giving low (1-3 questions), medium 
(4-6) questions) and high (7-8 questions) quality values. 
This analysis was carried out independently by each of 
the two investigators and in cases of disagreement, the 
third acted as a mediator.
-Summary measures:
All variables were collected in a database and analysed 
with SPSS v. 20.0 (IBM Corp. Released 2011. IBM 
SPSS Statistics for Windows, Version 20.0. Armonk, 
NY: IBM Corp.). For the univariate description, we 
used basic descriptive statistics, such as mean, standard 
deviation, frequency and percentage.
Results
-Study selection:
The search process involved a total of 66 articles, of 
which 36 were excluded because they were not articles 
on oral ulcers produced by MTX. After reading the lat-
ter, 16 met the aforementioned inclusion criteria (Fig. 1).
-Study characteristics:
Of the 16 articles, 2 were rated as high quality (12.5%), 2 
as low quality (12.5%) and 12 as medium quality (75%) 
(Table 1). The summary of data obtained from the pa-
tients extracted from the studies can be seen in Table 2.
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Fig. 1. Flow Diagram.
Authors Year Sample Quality
Kazlow et al. (36) 2003 1 Medium
Warner et al. (35) 2008 1 Low
Hocaoglu et al. (34) 2008 1 Low
Bookstaver et al. (33) 2008 1 Medium
Arvanitidou et al. (32) 2011 1 Medium
Hashizume et al. (31) 2012 1 Medium
Pastor-Nieto et al. (24) 2009 1 High
Kudoh et al. (23) 2014 1 Medium
Hanakawa et al. (22) 2013 1 Medium
Horie et al. (20) 2015 1 Medium
Deeming et al. (19) 2005 2 Medium
Troeltzsch et al. (16) 2013 2 Medium
Delyon et al. (7) 2015 5 Medium
Yelamos et al. (6) 2014 3 Medium
Dias Souza et al. (5) 2014 1 Medium
Katsoulas et al. (2) 2016 1 High
Table 1. Quality of the articles included in this systemic review.
The 16 articles involved a total of 24 patients and the 
epidemiological data are summarized in Table 3.
The mean age of the patients affected by oral ulcers 
was 65.45 years (standard deviation [SD]=13.20), with 
a range of 36-92 years.
In 8 patients, the location of the lesion was not specified 
(33.33%). In the four patients with a single lesion, two 
appeared in the retromolar area, another in the keratin-
ized gingiva and another in the lip.
All patients except for one took MTX subcutaneously 
(4.17%) and the rest took MTX orally (95.83%).
The mean time of evolution of the lesion before being 
treated by the medical service in patients who specified 
the time (50%) was 123.91 days (SD=309.81). However, 
one patient lived with the lesions for three years without 
being treated, which distorts the results. If we exclude 
this patient, the mean time of evolution of the lesions 
was 35.63 days (SD=52.57).














































































Katsoulas et al. (2) W 73 IM 5 WMtx Yes AR EBV(-), 
HSV/CMV (NS) 
Yes Yes 2,5 180 21 No Yes 0 
Dias Souza et al. (5) W 58 DE 1 WMtx+AF Sí P NS Yes Yes 10 0 28 NS NS 18 
Delyon et al. (7) M 71 DE NS WMtx+AF+Cd Yes P HSV(+), 
CMV/EBV(NS) 
No NS 20 24 7 NS NS 0 
Delyon et al. (7) M 45 DE NS WMtx+AF+Cd No P HSV (-), 
CMV/EBV(NS) 
No NS 10 6 5 NS NS 0 
Delyon et al. (7) W 64 UK NS WMtx+AF No AR HSV (-), 
CMV/EBV(NS) 
No No 15 48 14 NS NS 0 
Delyon et al. (7) W 69 UK NS AF  AR HSV(+), 
CMV/EBV(NS) 
No NS 10 60 14 NS NS 0 
Delyon et al. (7) W 92 DE NS WMtx+AF No Penf NS No NS 12,5 2 21 NS NS 0 
Yelamos et al. (6) M 63 DE 5 WMtx+AF+O No P NS No No 10 4 10 NS Yes 0 
Yelamos et al. (6) M 38 DE NS WMtx+AF No P NS No NS 10 0 31 NS Yes 0 
Yelamos et al. (6) M 84 IM NS WMtx+AF+O Exitus AR NS No NS 7,5 2 Exitus NS Yes 0 
Horie et al. (20) M 60 UK 30 WMtx NS AR EBV(+), 
HSV/CMV(NS) 
Yes Yes 6 240 NS NS Yes 6 
Kudoh et al. (23) W 75 LPD 30 WMtx+O No AR EBV(+), 
HSV/CMV(NS) 
No Yes 8 60 21 NS NS 48 
Hanakawa et al. (22) M 67 LPD 180 WMtx+O No AR EBV(+), 
HSV/CMV(NS) 
NS Yes 6 240 21 NS Yes 0 
Pastor-Nieto et al. (24) W 79 LPD 60 WMtx NS AR EBV(+), 
HSV/CMV(NS) 
No Yes 12,5 204 42 NS NS 18 
Troeltzsch et al. (16) W 71 IM 7 WMtx+O Yes AR NS No No 15 0 7 NS Yes 0 
Troeltzsch et al. (16) W 80 IM 1095 WMtx+AF NS AR NS No Yes 25 36 28 NS Yes 0 
Hashizume et al. (31) W 62 UK NS WMtx No Poli. CVM/EBV(+), 
HSV(NS) 
NS NS 10 84 31 NS Yes 0 
Arvanitidou et al. (32) W 65 NS 4 WMtx+Cd NS Leuc. NS NS NS 20 2 14 NS Yes 0 





Hoc oglu et al. (34) M 4 DE NS AF AR 5 0 NS NS 
Warner et al. (35) 36 WMtx S S 12,5 NS 14 
Deeming et al. (19) W 63 DE 10 WMtx+Cd Yes AR NS Yes NS 10 6 35 No Yes 0 
Deeming et al. (19) M 75 DE 60 RMtx+Cd Yes AR NS No NS 2,5 6 28 No Yes 6 
Kazlow et al. (36) M 58 UK NS WMtx NS P NS Yes NS 15 8 NS NS NS 0 
Table 2. Data patients extracted from the studies included in this systemic review
W: woman; M: man; NS: not specified; WMTx: abandonment of methotrexate; WMtx+AF: abandonment of methotrexate with folic acid; 
WMth+AF+Cd: abandonment of methotrexate, folic acid and topical use of corticosteroid treatments; AF: folic acid; WMtx+AF+O: abandon-
ment of methotrexate with folic acid and other treatments (antibiotics and systemic corticosteroids); WMtx+O: abandonment of methotrexate 
and other treatments (antibiotics or systemic corticosteroids); WMtx+Cd: abandonment of methotrexate and topical use of corticosteroid; 
RMtx+Cd: reduction of folic acid treatment and topical use of corticosteroids; W: female; M:male; IM: medication interaction; DE: wrong dose 
intake; UK: unknown; LDP: lymphoproliferative disorders; AR: rheumatoid arthritis; P: psoriasis; Penf.: pemphigus; Poli.: polymyositis; Leuc: 
T-cell lymphocytic leukemia.
The mean time of the patients in which the months 
were specified taking MTX (23/24) was 52.91 months 
(SD=80.75), with a range of 0-240 months.
Only 3 of the 24 patients specified their smoking habit 
and were non-smokers (12.5%). Only 12 of the 24 pa-
tients specified any concomitant medication (50%).
Regarding the healing time of oral ulcers in days, in 3 
patients the healing time was not specified and one pa-
tient died due to complications of MTX poisoning. In 
the remaining 20 patients, the mean healing time was 
19.9 days (SD=10.63).
The average dose of MTX prescribed to each patient 
was 10.93 mg/week (SD=5.45).
The most common management for healing oral ulcers 
was the abandonment of MTX and treatment with folic 
acid (29.17%), followed by simply the abandonment of 
MTX (25%). MTX was withdrawn in 12.5% of cases and 
patients were given other treatments, such as antibiotics 
and systemic corticosteroids. Other authors combined 
the cessation of MTX with folic acid and oral cortico-
steroid treatments (8.33%) or the cessation of MTX with 
folic acid and other drugs, such as systemic corticoste-
roids and antibiotics (8.33%), or simply the cessation of 
MTX combined with oral corticosteroids (8.33%). The 
least frequently used measures were simple treatment 
with folic acid (4.17%) and the reduction of folic acid 
treatment and the use of corticosteroids (4.17%). The 
average time of total healing of the oral lesions in each 
proposed management can be seen in Figure 2.
In total, 50% of the studies analysed specified the con-
comitant medication that the patient was taking (apart 
from MTX).
The number of patients who returned to MTX without 
suffering the reappearance of oral ulcers was 6 (25%), 
while 8 patients did not specify their return (33.33%) 
and 10 did not resume MTX (41.67%).
-Risk bias across studies:
All studies that fulfilled the inclusion criteria were “in 
relation to a case” and most included patients who were 
referred or admitted urgently to a maxillofacial or emer-
gency service in the hospital setting. Therefore, data on 
the patient’s history depended, to a large extent, on data 
that he/she contributed and not to previous monitoring. 
The follow-up duration was longer than one month in 
only 5 (20.83%) patients and the mean follow-up time of 
these patients was 19.2 months (SD=17.81).
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Only folic acid 
Reduction of MTX + topical corticoids 
Abandonment of MTX 
Abandonment of MTX + folic acid 
Abandonment of MTX + folic acid + topical corticoids 
Abandonment of MTX + topical corticoids 
Abandonment of MTX + folic acid + others (antibiotics/ systemic 
corticoids) 




































































Table 3. Descriptive statistics. 
NS: not specified; MTX: methotrexate; HSV: herpes simplex virus; CMV: cytomegalovirus; 
EBV: Epstein-Barr virus.
Discussion
The search to identify oral ulcers managed by MTX 
yielded a total of 16 articles, where most were classified 
as medium quality, with a total of 24 patients.
Despite the heterogeneity of the proposed management 
in the different studies, the majority (29.17%) opted for 
the abandonment of MTX and additional treatment with 
folic acid, followed by the simple abandonment of MTX 
(25%).
Studies on the adverse effects of MTX at low doses con-
clude that there is usually a dose-dependent relationship 
(category A), but there are insufficient data to differenti-
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ate MTX stomatitis from other entities, such as lichen-
oid reactions (8).
Authors such as Avery et al. claim that the most fre-
quent reasons for MTX toxicity are an increase in 
exposure to the drug due to an error in the dose ad-
ministered, to its interaction with other medications (es-
pecially antibiotics and nonsteroidal anti-inflammatory 
drugs, NSAIDs), renal failure, infections or advanced 
age (14, 15). This observation coincides with our results 
because the majority of oral ulcers due to MTX were as-
sociated with erroneous intake of the dose (85.43%) and 
drug interaction (specifically with ciprofloxacin, ibu-
profen and omeprazole) that occurred in 16.67% of the 
patient cases. Taking into account the non-negligible 
number of drugs that can interact with MTX increas-
ing its toxicity, one bias to be taken into account is that 
half of the studies included in this review did not record 
the patient’s medication or did not account for it when 
treating oral ulcers, since we did not observe the ces-
sation of any medication that could interact with MTX 
as a proposed management for oral ulcers in any of the 
articles studied.
The number of patients who returned to MTX without 
suffering a reappearance of oral ulcers was 6 (25%), 
while 8 did not specify (33.33%) and 10 did not resume 
MTX (41.67%). None of the articles specified why the 
patient decided to retake MTX, and there is controversy 
among authors who suggest that it can be safely retaken 
(6) and those who have registered a 50% relapse of pa-
tients a few days after the first event (2).
The most frequent localizations of the oral lesions pro-
duced by MTX are the lingual dorsum, the hard palate 
and the gingiva (16). In those single lesions, which were 
Fig. 2. Plot of means of oral ulcer management. WMTx: abandonment of methotrexate; WMtx+AF: abandonment of methotrexate with folic 
acid; WMth+AF+Cd: abandonment of methotrexate, folic acid and topical use of corticosteroid treatments; AF: folic acid; WMtx+AF+O: 
abandonment of methotrexate with folic acid and other treatments (antibiotics and systemic corticosteroids); WMtx+O: abandonment of 
methotrexate and other treatments (antibiotics or systemic corticosteroids); WMtx+Cd: abandonment of methotrexate and topical use of 
corticosteroid; RMtx+Cd: reduction of folic acid treatment and topical use of corticosteroids.
observed in 4 patients (16.66%), 2 appeared in the retro-
molar area, one in the keratinized gingiva and another 
in the lip. In cases of multiple lesions, ulcers appeared 
in labial, oral and keratinized mucosa.
Despite the effects that MTX toxicity can have on pa-
tients, MTX is more effective than other disease-mod-
ifying antirheumatic drugs (DMARDs), with more 
than half of patients experiencing at least one moderate 
improvement (8). This means that the complete cessa-
tion of MTX, without resuming, limits the options of 
patients who require treatment for their autoimmune 
disease.
Another adverse effect of MTX is the iatrogenic associ-
ation with lymphoproliferative disorders (LPDs). These 
disorders encompass multiple conditions in which lym-
phocytes are produced in excessive amounts, as in lym-
phomas, and are more frequent in immunocompromised 
patients. Since MTX is an immunosuppressive agent, it 
is also considered a common cause of iatrogenic LPDs 
associated with immunodeficiencies (17). Iatrogenic 
lymphoproliferative disorders are atypical lymphoid 
proliferations or lymphomas that affect patients treated 
with immunosuppressants. In 2008, the World Health 
Organization (WHO) classified iatrogenic immunode-
ficiency produced by MTX within this group (21). A 
higher incidence of lymphomas has been observed in 
patients with rheumatoid arthritis treated with MTX 
(22). In our review, LPDs due to MTX were associated 
with the appearance of oral ulcers in 3 patients (12.5%).
The clinical and histological characteristics of oral ul-
cers produced by MTX are not always diagnostic and an 
extensive clinicopathological investigation is necessary 
to exclude lymphoproliferative disorders; histopatho-
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logical analysis has revealed a broad spectrum, ranging 
from non-specific ulceration, lichenoid reactions or lym-
phoproliferative disorders (2). Of the studies analysed in 
this literature review, only 7 (29.17%) performed a biop-
sy of the oral ulcer and the results were different: poly-
morphous lymphohistiocytic proliferation with atypical 
binuclear lymphocytes (2); area covered by exudate and 
regenerating epithelium, ectasia in proliferative vessels 
and neutrophils at the bottom of the lesion (5); regen-
erative basal layer with multinuclear keratinocytes (7); 
proliferation of large lymphoid cells with excised nuclei 
containing conspicuous nucleoli (17); atypical lympho-
cytic infiltrate with prominent nucleoli in submucosal 
granulation tissues (18); numerous proliferations of 
large atypical lymphoid cells with small lymphocytes 
(19); dense infiltrate composed of large lymphoid cells 
with irregular margins that occupy the entire thickness 
of the mucous membrane (20); and irregular and hyper-
plastic epithelial layers with apoptotic cells, atypical 
nuclei and a lichenoid appearance (21).
The different responses to MTX treatment are believed 
to be due to the heterogeneity between patients related 
to the polymorphisms of the genes involved in the me-
tabolism of MTX or folic acid (22), the phenotype of 
the disease, and the previous duration of the disease, in 
addition to the factors associated with the absorption of 
the drug and its kinetics (4).
In 2010, Dojcinov et al. proposed positive mucocutane-
ous ulcers for EBV as a new clinicopathological entity 
in an article describing a series of ulcerative lesions 
with histological features, such as Hodgkin lymphoma 
associated with several types of immunosuppression 
(23).
Some authors have suggested that the presence of mul-
tiple painful oral ulcers covered by a necrotic pseudo-
membrane in medically compromised patients may be 
associated with HSV, CMV or HSV (16). In this review, 
two patients (8.33%) tested positive for HSV, 1 (4.17%) 
for CMV, and 5 (20.83%) for EBV.
An elevated level of liver enzymes, usually transami-
nases, is found in up to 70% of patients in the first 2 to 
4 years of treatment. Liver involvement was observed 
in 3 patients (12.5%), although in 11 patients (45.83%), 
the state of their liver was not specified. Kidney failure 
was more common than liver failure; it was recorded 
in 5 patients (20.83%). Myelosuppression is the most 
feared adverse effect. Among the most common entities 
are thrombocytopenia, leukopenia and pancytopenia 
(8). This result coincides with the results of our review, 
where 54.17% of patients presented some form of my-
elosuppression.
Some authors have reported ulcers induced by MTX in 
patients with preexisting folate deficiency. The elevated 
levels of MTX in saliva acting topically are considered 
the triggers of developing lesions. The measurement of 
MTX excreted in saliva has been proposed as a useful 
predictor of oral ulceration (8).
Most authors agree that the healing time of the ulcers 
is complete three weeks after stopping the medication 
(19). In our study, the mean healing time was 19.9 days. 
This average healing time cannot be taken as a meta-
analysis calculation since all the included studies are 
related to a report case or series of cases, and the het-
erogeneity among the studies is so great that it would 
not be appropriate to do a meta-analysis with the data 
provided. The objective of our work has been to carry 
out a systematic review on the management carried 
out in patients with oral ulcers by methotrexate at low 
doses, not a meta-analysis on the healing time or other 
variables described in this study.
Despite the rapid resolution, we should not forget the 
seriousness of not taking into account acute toxicity fol-
lowing a painful, non-traumatic oral ulcer that does not 
cease after 15 days of evolution. In the study by Yéla-
mos et al., of the 28 patients who were taking MTX at 
low doses and who suffered acute toxicity, 7 died (25%) 
(9). Another reason for worsening is that oral lesions 
are painful, which often prevents patients from eating, 
impairing their general health and decreasing folic acid 
due to a lack of nutrients (21).
Some studies have shown that folic acid supplementa-
tion in patients taking MTX reduces adverse mucosal 
and gastrointestinal effects by 39% (24, 25). Of the pa-
tients analysed in this review, only 5 took folic acid at 
the time the lesion appeared (20.83%), while 14 speci-
fied that they did not take it (58.33%).
Pearce and Wilson reviewed a total of 47 cases be-
tween 1951 and 1996 and found the simultaneous use 
of NSAIDs and advanced age as risk factors. (26). The 
average age of our patients was 65.45 years (SD=13.20) 
and drug interaction with ibuprofen occurred only in 2 
patients with oral ulcers.
The differential diagnosis of ulcerations of the oral mu-
cosa is extensive and includes recurrent aphthous sto-
matitis, autoimmune disorders, allergic reactions, viral 
and bacterial infections, coeliac disease, agranulocy-
tosis, syndromic diseases and adverse drug effects. A 
meticulous history and examination can elucidate the 
underlying cause (21).
An important interaction that dentists and maxillofacial 
specialists should consider is that nitrous oxide increas-
es the antifolate effect of MTX and its use as inhalation 
sedation should be avoided in these patients (27).
-Limitations:
All studies that fulfilled the inclusion criteria were “in 
relation to a case” and most included patients who were 
referred or urgently admitted to a maxillofacial or emer-
gency service in the hospital setting. This means that 
data on the patient’s history depended, to a large extent, 
on data provided by the patient and not to previous mon-
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itoring. In addition, due to the aforementioned charac-
teristics, it was not possible to perform an exhaustive 
follow-up to assess the patients after the event.
Conclusions
Evidence on the management of oral ulcers in the oral 
cavity produced by MTX is scarce due to the heteroge-
neity of data and the measures adopted in the different 
studies selected to manage these lesions. Therefore, it 
seems that this management is relegated to the percep-
tion of the clinician rather than to a specific protocol of 
action. Studies with a longer follow-up duration and an 
analysis of oral ulcers are necessary to guide different 
health professionals in their management.
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